High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival
- PMID: 37857854
- PMCID: PMC10587349
- DOI: 10.1038/s41698-023-00455-z
High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival
Abstract
Numerous cell states are known to comprise the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME). However, the developmental stemness and co-occurrence of these cell states remain poorly defined. Here, we performed single-cell RNA sequencing (scRNA-seq) on a cohort of treatment-naive PDAC time-of-diagnosis endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) samples (n = 25). We then combined these samples with surgical resection (n = 6) and publicly available samples to increase statistical power (n = 80). Following annotation into 25 distinct cell states, cells were scored for developmental stemness, and a customized version of the Ecotyper tool was used to identify communities of co-occurring cell states in bulk RNA-seq samples (n = 268). We discovered a tumor microenvironmental community comprised of aggressive basal-like malignant cells, tumor-promoting SPP1+ macrophages, and myofibroblastic cancer-associated fibroblasts associated with especially poor prognosis. We also found a developmental stemness continuum with implications for survival that is present in both malignant cells and cancer-associated fibroblasts (CAFs). We further demonstrated that high-dimensional analyses predictive of survival are feasible using standard-of-care, time-of-diagnosis EUS-FNB specimens. In summary, we identified tumor microenvironmental and developmental stemness characteristics from a high-dimensional gene expression analysis of PDAC using human tissue specimens, including time-of-diagnosis EUS-FNB samples. These reveal new connections between tumor microenvironmental composition, CAF and malignant cell stemness, and patient survival that could lead to better upfront risk stratification and more personalized upfront clinical decision-making.
© 2023. Nature Publishing Group UK.
Conflict of interest statement
E.S. and A.A.C. have patent filings related to cancer biomarkers. F.Q. has stock options in Centene, Gilead, and Horizon Therapeutics. H.K. has received research funding, travel accommodations, and honoraria from Varian Medical Systems and from ViewRay, and has consulted for Varian Medical Systems. W.G.H. is a member of the board of directors for Accuronix Therapeutics. A.A.C. has licensed technology to Droplet Biosciences, LiquidCell Dx, Tempus Labs, and Biocognitive Labs. A.A.C. has served as a consultant/advisor to Roche, Tempus, Geneoscopy, Illumina, Invitae, Myriad Genetics, NuProbe, Daiichi Sankyo, AstraZeneca, AlphaSights, DeciBio and Guidepoint. A.A.C. has received honoraria from Roche, Foundation Medicine, Agilent, and Dava Oncology. A.A.C. has stock options in Geneoscopy, research support from Roche, Illumina, and Tempus Labs, and ownership interests in Droplet Biosciences and LiquidCell Dx. No potential conflicts of interest were disclosed by the other authors.
Figures



References
-
- Cancer of the Pancreas—Cancer Stat Facts. SEERhttps://seer.cancer.gov/statfacts/html/pancreas.html (2020).
-
- Bailey P, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous